

MAR. 17. 2004 4:36PM

GLAXO WELLCOME

NO. 2870 P. 1

FAX

To 1614
.....
Company USPTO
.....
Fax 703-872-9306
.....
From Allyson K. Jacobs
.....
Tel 919-483-9105 Fax 919-483-7988
.....
E-mail aki27836@glaxowellcome.com
.....
Date 17-Mar-04 Pages including cover 17
.....
Subject Serial No.: 10/062,647
.....
Filing Date: 1/31/02
.....

Attached:

Amendment Transmittal
Amendment
Copy of Previously Filed Terminal Disclaimer
Certificate of Transmission




Glaxo Wellcome Inc.
PO Box 13398
Five Moore Drive
Research Triangle Park
North Carolina 27709
Tel: 919 483 2100
www.gsk.com

RECEIVED
CENTRAL FAX CENTER

MAR 17 2004

OFFICIAL

The information contained in these documents is confidential and may also be privileged and is intended for the exclusive use of the addressee designated above. If you are not the intended recipient or the employee or agent responsible to deliver it to the intended recipient, any disclosure, reproduction, distribution, or any other dissemination or use of this communication is strictly prohibited. If you have received this transmission in error please contact us immediately by telephone so that we can arrange for its return.

AMENDMENT TRANSMITTAL LETTER (Large Entity)				Docket No. PG3119USW	
Applicant(s): Cockerill et al.					
Serial No. 10/062,647	Filing Date 1/31/02	Examiner Rebecca Cook		Group Art Unit 1614	
Invention: FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS					
<u>TO THE COMMISSIONER FOR PATENTS:</u>					
Transmitted herewith is an amendment in the above-identified application. The fee has been calculated and is transmitted as shown below.					
CLAIMS AS AMENDED					
	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	23 -	23 -	0 x	\$18.00	\$0.00
INDEP. CLAIMS	1 -	3 -	0 x	\$86.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT					\$0.00
 <input checked="" type="checkbox"/> No additional fee is required for amendment. <input type="checkbox"/> Please charge Deposit Account No. _____ in the amount of _____ <input type="checkbox"/> A check in the amount of _____ to cover the filing fee is enclosed. <input checked="" type="checkbox"/> The Director is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 07-1392 <input checked="" type="checkbox"/> Any additional filing fees required under 37 C.F.R. 1.16. <input checked="" type="checkbox"/> Any patent application processing fees under 37 CFR 1.17.					
 Signature John L. Lemanowicz, Reg. No. 37,380 Attorney for Applicants GlaxoSmithKline Five Moore Drive, PO Box 13398 Research Triangle Park, NC 27709-3398 Telephone: (919) 483-8247 Facsimile: (919) 483-7988			Dated: 3/17/2004		
CC:			<div style="font-size: small;">I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37C.F.R. 1.8 and is addressed to the for Patents, P.O. Box 1450, ALEXANDRIA, VA 22313-1450.</div>		
			Signature of Person Mailing Correspondence		
			Typed or Printed Name of Person Mailing Correspondence		

P11LARGE/REV03

MAR. 17. 2004 4:37PM

GLAXO WELLCOME

NO. 2870 P. 3

Atty. Docket No.: PG3119US2

RECEIVED
CENTRAL FAX CENTER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAR 17 2004

In re Application of: Cockerill et al

Serial No.: 10/062,647

Examiner: J. Goldberg

Filing Date: January 31, 2002

Art Unit: 1614

For: FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE
INHIBITORS

Commissioner for Patents
Washington D.C. 20231

OFFICIAL

AMENDMENT

Sir:

This paper is being filed in response to the Office Action mailed December 17, 2003. Accordingly, this paper is timely filed on or before March 17, 2004. Reconsideration of the application in view of the amendment and remarks following is earnestly solicited.

Please amend the above-identified application as follows:

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 12 of this paper.